The proceeding

The proceeding is Merck Sharp & Dohme LLC v. Halozyme, Inc., PGR2025-00042, on U.S. Patent 12,037,618 B2. Administrative Patent Judges Jeffrey N. Fredman, Susan L. C. Mitchell, and Cynthia M. Hardman sat on the panel, and Administrative Patent Judge Mitchell wrote the opinion. The decision (Paper 95) is a final written decision dated November 9, 2026, entered under 35 U.S.C. 328(a). Merck Sharp & Dohme LLC is the petitioner and identifies itself as the real party in interest. Halozyme, Inc. is the patent owner and identifies itself and one other company as the real parties in interest.

U.S. Patent 12,037,618 B2 is titled "PH20 polypeptide variants, formulations and uses thereof." The decision states that it issued on July 16, 2024, from U.S. Application 17/327,586, filed May 21, 2021. The decision describes the patent as drawn to modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity.

Institution

Merck requested post-grant review of all claims of the '618 patent, claims 1-40. Halozyme statutorily disclaimed claims 3, 4, 6, and 34-40, leaving claims 1, 2, 5, and 7-33, and did not file a preliminary response. The Director ruled on discretionary denial, and the case was referred to a Board panel. On November 13, 2025, the Board instituted trial of claims 1, 2, 5, and 7-33. The decision states that the '618 patent was eligible for post-grant review and that at least one challenged claim was more likely than not unpatentable. 35 U.S.C. 324(a) uses that standard for institution of post-grant review. The oral hearing was July 23, 2026.

The Board later denied Halozyme's motion to terminate (Paper 81). Halozyme requested Director Review of that order (Paper 88), and the request was not considered because it "is outside the scope of Director Review."

The claim and the grounds

Claim 1 of the patent, which the decision identifies as the sole independent claim, reads: "1. A modified PH20 polypeptide, comprising one or more amino acid modifications in an unmodified PH20 polypeptide, wherein: the unmodified PH20 polypeptide consists of the amino acid sequence selected from the group consisting of SEQ ID NO: 3, 7 and 32-66; amino acid modifications are selected from among amino acid replacements, deletions, and/or insertions; the modified PH20 polypeptide comprises a modification at a position corresponding to position 309 with reference to amino acid positions of SEQ ID NO: 3; corresponding amino acid positions are identified by alignment of the PH20 polypeptide with the polypeptide having the amino acid sequence of SEQ ID NO: 3; and the modified PH20 polypeptide has at least 91% sequence identity to the amino acid sequence selected from the group consisting of SEQ ID NO: 3, 7 and 32-66."

The Board construed "modified PH20 polypeptide" to require a polypeptide that has hyaluronidase activity, interpreting the term in light of the patent's specification. It rejected Halozyme's position that the claims recite a modified PH20 polypeptide in purely structural terms.

The grounds table lists three grounds. Ground 1 is written description under 35 U.S.C. 112, claims 1, 2, 5, and 7-33. Ground 2 is enablement under 35 U.S.C. 112, claims 1, 2, 5, and 7-33. Ground 3 is obviousness under 35 U.S.C. 103 over the '429 patent and Chao, claims 1, 2, 5, 7-22, and 24-33. Merck originally challenged claims 1-40 for lack of written description and enablement, and claims 1, 2, 4, 5, 7-22, and 24-40 for obviousness; the Board adjusted those sets to the claims remaining after the disclaimer. The decision identifies the '429 patent as U.S. Patent 7,767,429 B2, issued August 3, 2010, and Chao as Chao et al., Structure of Human Hyaluronidase-1, a Hyaluronan Hydrolyzing Enzyme Involved in Tumor Growth and Angiogenesis, 46 Biochemistry 6911-6920 (2007).

The judgment

The decision states that the petitioner must prove unpatentability by a preponderance of the evidence. 35 U.S.C. 326(e). The Board found that Merck had made that showing for written description and for enablement. On written description, the Board wrote that Halozyme "claims an immense number of mutations in the PH20 polypeptide, but provides insufficient guidance for a POSA as of 2011-2012 to determine which, if any, of the untested multiple mutated forms will retain hyaluronidase activity." On enablement, the Board found that undue experimentation would have been required to enable the broad scope of the claims.

The Board also addressed Halozyme's position that the term is broader and includes inactive polypeptides that can be used as antigens to provide a contraceptive effect. Even under that position, the Board found that the evidence did not show that a person of ordinary skill would have understood the inventors to be in possession of the full scope of the recited polypeptides capable of such use, and that identifying which, if any, modified polypeptides are useful for that purpose would also have required undue experimentation. The decision describes the enablement finding on that point as an alternative finding premised on Halozyme's claim construction, which the Board did not adopt.

On obviousness, the decision states that it is undisputed that neither the '429 patent nor Chao specifically identifies or discusses position 309 of the PH20 polypeptide. The Board found that Merck had not shown, by a preponderance of the evidence, that the combination of the '429 patent and Chao, with the knowledge and teaching described by two of Merck's declarants, demonstrates obviousness for the claims of the '618 patent, and wrote that Merck had not shown specific reasons to modify position 309 of the PH20 polypeptide.

The summary table lists claims 1, 2, 5, and 7-33 as shown unpatentable for lack of written description and for lack of enablement, and lists claims 1, 2, 5, 7-22, and 24-33 as not shown unpatentable over the '429 patent and Chao. The order states that claims 1, 2, 5, and 7-33 of U.S. Patent 12,037,618 B2 are determined to be unpatentable, and requires a party seeking judicial review to comply with the notice and service requirements of 37 C.F.R. 90.2.

The New Jersey case

The decision states that the '618 patent is subject to Halozyme, Inc. v. Merck Sharp & Dohme LLC f/k/a Merck Sharp & Dohme Corp., No. 2:25-cv-03179 (D.N.J.), and lists U.S. Patents 12,077,791, 12,195,773, and 12,110,520 among the other patents in that case. Halozyme's April 24, 2025 complaint asserts the '618 patent and fourteen other patents against Merck. The decision's table of related reviews includes PGR2025-00017, on the '520 patent, and PGR2025-00050 and PGR2025-00053, on the '791 and '773 patents.

On August 6, 2026, Magistrate Judge Jose R. Almonte administratively stayed No. 2:25-cv-03179 pending the outcome of the patent reviews before the Patent Trial and Appeal Board and, if applicable, the Federal Circuit (D.I. 65).

What to watch next

Watch for a notice of appeal. Under 35 U.S.C. 141(c), a party to a post-grant review who is dissatisfied with a final written decision under 35 U.S.C. 328(a) may appeal the Board's decision only to the United States Court of Appeals for the Federal Circuit. 37 C.F.R. 90.2 sets the notice and service requirements for that appeal. Also watch for further orders in the stayed New Jersey case. The case can end at any time, including by settlement or voluntary dismissal.